Pharmaceutical applications of cyclodextrins .3. Toxicological issues and safety evaluation

被引:772
作者
Irie, T [1 ]
Uekama, K [1 ]
机构
[1] KUMAMOTO UNIV, FAC PHARMACEUT SCI, KUMAMOTO 862, JAPAN
关键词
D O I
10.1021/js960213f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objective of this review is to summarize recent findings on the safety profiles of three natural cyclodextrins (alpha-, beta- and gamma-CDs) and several chemically modified CDs. To demonstrate the potential of CDs in pharmaceutical formulations, their stability against non-enzymatic and enzymatic degradations in various body fluids and tissue homogenates and their pharmacokinetics via parenteral, oral, transmucosal, and dermal routes of administration are outlined. Furthermore, the bioadaptabilities of CDs, including in vitro cellular interactions and in vivo safety profiles, via a variety of administration routes are addressed. Finally, the therapeutic potentials of CDs are discussed on the basis of their ability to interact with various endogenous and exogenous lipophiles or, especially for sulfated CDs, their effects on cellular processes mediated by heparin binding growth factors.
引用
收藏
页码:147 / 162
页数:16
相关论文
共 201 条
[1]   EFFECT OF CYCLODEXTRINS AND UNDIGESTED STARCH ON THE LOSS OF CHENODEOXYCHOLATE IN THE FECES [J].
ABADIE, C ;
HUG, M ;
KUBLI, C ;
GAINS, N .
BIOCHEMICAL JOURNAL, 1994, 299 :725-730
[2]   COMBINED USE OF 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN AND A LIPOPHILIC ABSORPTION ENHANCER IN NASAL DELIVERY OF THE LHRH AGONIST, BUSERELIN ACETATE, IN RATS [J].
ABE, K ;
IRIE, T ;
ADACHI, H ;
UEKAMA, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 123 (01) :103-112
[3]  
Abe K, 1995, CHEM PHARM BULL, V43, P2232
[4]  
Abe K., 1995, PHARM SCI, V1, P563
[5]   COMBINATION EFFECTS OF O-CARBOXYMETHYL-O-ETHYL-BETA-CYCLODEXTRIN AND PENETRATION ENHANCER HPE-101 ON TRANSDERMAL DELIVERY OF PROSTAGLANDIN-E(1) IN HAIRLESS MICE [J].
ADACHI, H ;
IRIE, T ;
UEKAMA, K ;
MANAKO, T ;
YANO, T ;
SAITA, M .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1993, 1 (03) :117-123
[6]  
ADACHI H, 1992, J PHARM PHARMACOL, V44, P1033
[7]   BIOAVAILABILITY OF LEUPROLIDE ACETATE FOLLOWING NASAL AND INHALATION DELIVERY TO RATS AND HEALTHY HUMANS [J].
ADJEI, A ;
SUNDBERG, D ;
MILLER, J ;
CHUN, A .
PHARMACEUTICAL RESEARCH, 1992, 9 (02) :244-249
[8]   EPITHELIAL TRANSPORT AND BIOAVAILABILITY OF INTRANASALLY ADMINISTERED HUMAN GROWTH-HORMONE FORMULATED WITH THE ABSORPTION ENHANCERS DIDECANOYL-L-ALPHA-PHOSPHATIDYLCHOLINE AND ALPHA-CYCLODEXTRIN IN RABBITS [J].
AGERHOLM, C ;
BASTHOLM, L ;
JOHANSEN, PB ;
NIELSEN, MH ;
ELLING, F .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (12) :1706-1711
[9]   Cyclodextrin derivatives in pharmaceutics [J].
Albers, E ;
Muller, BW .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1995, 12 (04) :311-337
[10]   SUPPRESSION OF COLDS IN HUMAN VOLUNTEERS CHALLENGED WITH RHINOVIRUS BY A NEW SYNTHETIC DRUG (R61837) [J].
ALNAKIB, W ;
HIGGINS, PG ;
BARROW, GI ;
TYRRELL, DAJ ;
ANDRIES, K ;
VANDENBUSSCHE, G ;
TAYLOR, N ;
JANSSEN, PAJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) :522-525